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 Reduced ovarian function is associated with development of the metabolic 
syndrome (MetS).  Increased risk for MetS is strongly linked to hepatic metabolic 
dysfunction. However, at this time few studies have examined metabolic function of 
hepatic tissue under conditions of reduced ovarian function. The purpose of this study 
was to determine if ovariectomy (OVX) impaired hepatic mitochondrial function and 
its potential association with sirtuin (SIRT) function. Female C57BL/6 mice were 
divided into two groups (SHAM, OVX). Hepatic mitochondrial function was 
measured by assessing oxygen consumption, reactive oxygen species (ROS) 
production, and mitochondrial protein content. In addition, mitochondrial acetylation 
status and SIRT protein content was determined. The OVX group exhibited increased 
ROS production compared to the SHAM group. However, no differences were 
detected in oxygen consumption, mitochondrial protein content, acetylation status, or 
total SIRT content between groups. The data shows that ovariectomy increases 
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Metabolic-related diseases such as cardiovascular disease and type 2 diabetes are 
currently among the leading causes of mortality in the Western world. The majority of 
metabolic diseases are associated with obesity, making them a major concern in the United 
States, where over 30% of Americans are classified as obese and another third as overweight 
(Menifield et al, 2008).  Both a sedentary lifestyle and increased caloric consumption 
contribute to the onset of obesity and increase the susceptibility to a constellation of 
conditions such as hypertension, dyslipidemia, insulin resistance, and hyperglycemia. The 
onset of any of these conditions increases the risk for mortality, and when at least three of the 
afore-mentioned conditions are present it becomes known as the metabolic syndrome (MetS). 
Epidemiological studies show that post-menopausal women are at a higher risk for 
developing the MetS than their pre-menopausal counterparts, resulting in a substantial 
increase in the mortality risk in this population (Polotsky & Polotsky, 2010). Further, 
estrogens appear to play a key role in the regulation of a number of metabolic processes that 
would be predicted to protect women from metabolic disease.  Thus, any condition that 
results in the attenuation or ablation of estrogen function would likely increase the risk of 
developing metabolic disease. 
Independent of obesity, individuals with the MetS have up to five-fold more stored 
lipid in the liver than those without the MetS (Kotronen et al., 2008). Accordingly, increased 
liver fat content is strongly associated with the development of insulin resistance, which is a 
characteristic of the MetS (Eckles et al., 2005).  Enhanced lipid deposition in the liver 
decreases hepatic insulin sensitivity, resulting in increased gluconeogenesis and VLDL 




ovarian function in post-menopausal women is associated with metabolic abnormalities that 
increase the susceptibility for insulin resistance, central obesity, and dyslipidemia (Qureshi et 
al., 2007; Chow et al., 2011). Recent data suggest that the loss of estrogen function leads to 
insulin resistance in the hepatic tissue, suggesting that estrogens play a key role in defining 
hepatic metabolic function (Stubbins et al. 2011). Unfortunately, we have a poor 
understanding of the key factors contributing to the development of insulin resistance in the 
liver under conditions of reduced estrogen function.   
Individuals diagnosed with the MetS often exhibit non-alcoholic fatty liver disease 
(NAFLD), a condition characterized by the accumulation of hepatic fat making up more than 
5% of the total liver weight. NAFLD is the most prevalent form of liver disease worldwide 
and affects 95% of obese individuals (Basaranoglu et al., 2010). The increased fat storage 
can result in the development of insulin resistance (Satia-Abouta et al., 2002), and if left 
untreated NAFLD can progress into non-alcoholic steaohepatitis, fibrosis, cirrhosis, and 
hepatic carcinoma (Day, 2002).  Recent data have shown that the incidence of NAFLD is 
most frequent in older sedentary men, with growing evidence suggesting that fatty liver 
develops in women who are in states of estrogen deficiency (Lin et al., 2006). We have 
previously found that the surgical removal of the ovaries in the mouse contributes to 
increased hepatic lipid accumulation (Jackson et al., 2011), which is confirmed by similar 
findings by Stubbins et al. (2011), Kamada et al., (2011), and Rogers et al., (2009). This 
occurs even though the animals were maintained on a low-fat rodent chow, indicating the 
importance of estrogens in the maintenance of liver metabolic function in females.  
Furthermore, the Aromatase knockout male mouse (ArKO), which is unable to produce 




reversed by the administration of either exogenous estradiol (Hewitt et al., 2004) or an 
estrogen receptor agonist (Chow et al., 2011). In humans, 43% of female cancer patients 
developed hepatic steatosis within two years of Tamoxifen treatment, which is an estrogen 
receptor antagonist (Nishino et al., 2003). Collectively, these studies provide compelling 
evidence that the loss of ovarian hormone function is associated with abnormalities in hepatic 
metabolism.  
Under conditions of reduced ovarian function, one of the contributing factors to 
hepatic fat accumulation is the onset of visceral adiposity. Studies show that free fatty 
acids (FFAs) released via visceral adipose tissue lipolysis are the predominant source of 
stored hepatic lipid in patients with NAFLD (Thorne et al., 2010). Unlike the 
subcutaneous fat depot, FFAs derived from visceral adipose tissue have direct access to 
the liver through the hepatic portal vein. We have previously shown that there is a 
substantial increase in visceral adiposity in the ovariectomized (OVX) mouse model when 
compared to the age-matched controls (Wohlers & Spangenburg, 2010).  This increase in 
visceral adiposity is also seen in other models of reduced estrogen function such as the 
ArKO (Chow et al., 2011) and estrogen receptor alpha knockout (ERKO) (Bryzgalova et 
al., 2006). Our data also indicate that OVX mice have a loss of regulatory control over 
basal lipolytic function (Wohlers et al., 2011), resulting in enhanced FFA release from the 
visceral depot into the portal vein where the FFAs have direct access to the hepatic tissue. 
Therefore, it is likely that the enhanced rate of basal lipolysis in the OVX animal increases 
the rate of FFA transport through the portal vein, ultimately resulting in increased lipid 
deposition in the liver. The development of fatty liver due to increased lipolysis in visceral 




hypothesis could explain why most of the obese population exhibits NAFLD, and why 
increased visceral fat mass in postmenopausal women puts them at a higher risk for 
NAFLD.   
At this point, there is a relatively poor understanding of how estrogens regulate lipid 
metabolism within hepatic tissue.  Under conditions of reduced estrogen function, the 
accumulation of hepatic lipid could be due to either enhanced lipid storage or poor lipid 
utilization.  The formation of triacylglycerol (TAG), which comprises most of the lipid 
stored in the liver, can either be derived from FFAs in circulation or by synthesis of FA 
through de novo lipogenesis (DNL). Lipogenesis, or the assembly of FAs from glucose 
derivatives, is enzymatically regulated by Acetyl CoA Carboxylase (ACC) and Fatty Acid 
Synthase (FAS). Pighon et al., (2011) found that the hepatic mRNA expression of ACC 
and FAS as well as their transcription factor, sterol regulatory element-binding protein 
(SREBP-1c) were enhanced in OVX rats compared to SHAM rats  (Pighon et al., 2011).  
Furthermore, ArKO mice have increased hepatic FAS mRNA and protein expression 
(Chow et al., 2011).  In contrast, my group has failed to see any changes in the protein 
content of ACC or FAS in livers from OVX mice compared to SHAM mice.  Further, we 
failed to detect any difference in the lipogenic index (16:0/18:2n-6), suggesting the 
accumulation of TAG in the liver of the OVX mice is not the result of enhanced 
lipogenesis (Jackson et al., 2011).  The discrepancies between our data and those of 
Pighon et al. (2011) may be explained by the species-specific differences in the response 
to OVX, specifically, rats significantly increase their food intake in response to OVX 
(Paquette et al., 2007), while mice do not (Rogers et al, 2009). Thus, it is possible that the 




caloric consumption rather than a loss of ovarian function. In addition, we have also failed 
to see changes in mRNA expression of TAG assembly proteins such as diacylglyceol 
transferase (DGAT-1) and (DGAT-2) (Jackson et al., 2011), suggesting that the increase 
in hepatic TAG content is not a result of increased esterification of FFA.  
However, we have found significant differences in the FA composition of TAG 
isolated from hepatic tissue of OVX mice compared to SHAM mice. We have shown that 
OVX mice have proportionately higher levels of the monounsaturated FAs, palmitoleic 
(16:1) and oleic (18:1) acids, than the saturated FAs palmitic (16:0) and stearic (18:0) acid 
(Jackson et al., 2011). The ratio between the monounsaturated to the saturated forms of 
FAs is known as the desaturase index, which is used as a measure of the conversion of 
saturated FAs into monounsaturated FAs (Kotronen et al., 2009). This conversion is 
regulated by the enzyme stearoyl Coa desaturase (SCD-1). Increased hepatic SCD-1 
activity is associated with increased lipid storage in the liver, as well as hepatic insulin 
resistance (Cohen et al., 2003; Choi et al., 2011).  Our lab has found a significant increase 
in hepatic SCD-1 protein content in OVX mice, suggesting the increased TAG in the 
desaturase index is the result of an upregulation in SCD-1 protein content (Jackson et al., 
2011).  Furthermore, we found that by providing the OVX mice access to voluntary 
running wheels we were able to completely prevent the increases in SCD-1 content , 
desaturase index, and hepatic TAG content when compared to sedentary OVX mice.  At 
this time it is unclear why exercise prevented an increase in SCD-1 activity, however we 
have hypothesized this could be a result of increased oxidation of the FFA’s by the hepatic 




Therefore, if exercise can prevent increased hepatic lipid storage in OVX mice, it 
might be speculated that hepatic mitochondrial dysfunction is a contributor to 
accumulation of hepatic TAG accumulation.  This speculation is based on data by others 
showing that modest amounts of exercise training increase hepatic mitochondrial function 
and prevent the onset of NAFLD in animals that are extremely susceptible to metabolic 
diseases (Rector et al., 2008).  These authors suggested that the prevention of NAFLD is 
mediated by improvements in mitochondrial function.  However, at this time there are few 
data examining hepatic mitochondrial function in animal models of reduced estrogen 
function, with the exception of Paquette et al. (2009) who demonstrated a 34% reduction 
in oxidation of 9,10-[3-H] palmitate in isolated hepatocytes of OVX rats.  Thus, it is 
critical to undertake more studies to dissect the possibility that mitochondrial dysfunction 
may exist in hepatic tissue under conditions of reduced ovarian function. 
 A challenging issue in studying the OVX mouse model is that it often does not 
mimic other animal models of obesity when examining alterations in metabolic 
mechanisms.  Thus, it has been difficult to derive hypotheses based on traditional 
literature searches.  However, a recent publication described the development of the 
sirtuin3 knockout mouse (SIRT3 KO), which has a remarkably similar hepatic phenotype 
to what we have found in the OVX mouse model. Specifically, the SIRT3 KO mouse not 
only develops hepatic lipid accumulation, but it also has a similar gene profile to our OVX 
mouse model (Hirschey et al., 2011). The development of metabolic dysfunction in the 
SIRT3 KO mouse is a result of impaired mitochondrial function that occurs as a result of 




 Sirtuins (SIRT) are a family of deacetylases, which are involved in the post-
translational modification of proteins through the removal of acetyl groups (Finkel et al., 
2009;  Lombard et al., 2007). Acetylation is a form of post-translational modification 
mediated by the addition of acetyl groups to lysine residues within the protein sequence.  
The activities of SIRT1 and SIRT3 are mediated by changes in NAD+ levels, and thus it is 
largely affected by changes in nutrient flux to the cell (Imai et al., 2000; Lombard et al., 
2007).  For example, in cases of caloric excess, the decrease in the NAD+/NADH ratio 
suppresses SIRT3 activity resulting in increased acetylation of proteins (Kendrick. et al., 
2011), while fasting increases SIRT3 activity leading to deacetylation (Hirschey et al., 
2010). When mitochondrial protein acetylation is increased, enzymes involved in lipid 
oxidation (i.e. long chain acylCoA dehydrogenase and succinate dehydrogenase) decrease 
their function, resulting in an impaired abolity to oxidize lipid (Hirschey et al., 2010).   
 In a similar fashion to the OVX mouse, SIRT3KO mice develop normally, but 
eventually develop visceral adiposity, fatty liver, and glucose intolerance (Hirschey et al., 
2011).  Also, like the OVX mouse SIRT3KO mice exhibit significant increases in hepatic 
SCD-1 levels with no changes in regulators of hepatic de novo lipogenesis (Hirschey et 
al., 2011). Instead, the SIRT3KO exhibit abnormalities in mitochondrial function that are 
mediated by hyperacetylation of specific mitochondrial proteins (Lombard et al., 2007; 
Hirschey et al., 2011; Kendrick et al., 2011). To date, one hundred and thirty three 
different mitochondrial proteins have been identified as regulated by acetylation including 
enzymes in the TCA cycle, gluconeogenesis, and β-oxidation (Hirschey et al., 2010; Kim 
et al., 2006). For example, acetylation of succinate dehydrogenase (SDH) leads to a 




(Cimen et al., 2010). Acetylation is increasingly being recognized as a cellular regulatory 
mechanism that plays a role in metabolic disorders.  For instance, chronic high fat feeding 
induces hypercetylation of mitochondrial hepatic proteins, a reduction in SIRT3 activity, 
and the development of fatty liver and glucose intolerance (Kendrick. et al., 2011) 
(Hirschey et al., 2011).  
 These data suggest that acetylation and SIRT3 activity play an important role in 
mitochondrial function, however to the best of our knowledge no link has ever been found 
between estrogen status and SIRT regulation of mitochondrial function in hepatic tissue. 
Due to the qualitative similarities between the OVX model and the SIRT3KO mice ,it is 
possible that ovarian hormones affect hepatic mitochondrial function by regulating protein 
acetylation patterns. Thus, it is possible that any changes in mitochondrial function in the 
OVX model may be mediated by alterations in acetylation due to changes in SIRT 
function. 
Our previous studies show the increase in lipid accumulation in hepatic tissue is 
not mediated by increased lipogenesis or FA esterification (Jackson et al., 2011).  This 
could suggest that the increased hepatic TAG accumulation in OVX mice is not the result 
of increased rates of lipid storage, but of decreased rates of lipid utilization by the 
mitochondria that could be associated with increased acetylation of mitochondrial 
proteins.  At this time, few data exist which examine the effects of ovarian hormones on 
hepatic mitochondrial function and acetylation patterns.  Therefore, the objective of these 
experiments was to determine whether the surgical removal of the ovaries resulted in 
changes in hepatic mitochondrial function, in order to better define why mice have 





Overall Purpose: The purpose of this study was to determine if the loss of ovarian 
function in female mice results in impaired hepatic mitochondrial function.  
 
OVERALL HYPOTHESIS: Ovariectomy leads to hepatic lipid accumulation due to the 
development of mitochondrial dysfunction when compared to intact SHAM controls. 
 
SPECIFIC AIM 1: To determine if OVX mice exhibit reduced hepatic mitochondrial 
function compared to SHAM mice. 
RATIONALE: The accumulation of lipid within a tissue in the form of TAG is either 
the result of enhanced anabolic processes or reduced catabolic processes.  Previous 
data from our lab failed to demonstrate an upregulation of mechanisms that would be 
expected to contribute to increased TAG formation, thus we are hypothesizing the 
increases in TAG content are due to mitochondrial dysfunction.  To the best of my 
knowledge, no data have been published measuring mitochondrial function in the 
liver from the OVX mouse model.  Thus, this study seeks to determine if an increase 
in hepatic TAG content is associated with mitochondrial dysfunction, which is 
defined as reduced respiration rates coupled with increased reactive oxygen species 
(ROS) production when provided with adequate metabolic substrate. 
HYPOTHESIS 1:  Livers from OVX mice will exhibit increased lipid storage  
   compared to SHAM mice. 
HYPOTHESIS 2:  Mitochondria isolated from hepatic tissue of OVX mice will 
   exhibit reduced respiration rates compared to mitochondria  




HYPOTHESIS 3:  Mitochondria isolated from hepatic tissue of OVX mice will 
   exhibit increased ROS production rates compared to  
   mitochondria from hepatic tissue in SHAM mice 
 
SPECIFIC AIM 2: To determine if acetylation patterns of hepatic mitochondrial 
proteins differ in OVX mice compared to SHAM mice.  
RATIONALE: Qualitatively, the OVX mouse model has a similar hepatic phenotype and 
gene expression profile to the SIRT3KO mouse. Specifically, both accumulate hepatic 
TAG and have impaired glucose tolerance without changes in food intake.  The increased 
TAG content in the SIRT3KO mouse is the result of impaired lipid oxidation that results 
from the hyperacetylation of mitochondrial proteins.  Due to the similarities between the 
OVX and SIRT3KO mice, it is possible for hepatic mitochondrial acetylation to be altered 
under states of estrogen deficiency. Therefore, OVX mice may have alterations in hepatic 
mitochondrial function resulting from alterations in acetylation and SIRT function. To 
date, we are not aware of any published experiments testing this hypothesis. 
HYPOTHESIS 1:  Mitochondria isolated from hepatic tissue of OVX mice will 
   exhibit hyperacetylation compared to mitochondria from  
   hepatic tissue in SHAM mice. 
HYPOTHESIS 2:  Hyperacetylation in OVX hepatic mitochondrial proteins will 









Animal care: Twenty-six eight-week-old C57BL/6 female mice were divided into two 
groups. One group underwent bilateral ovariectomy (OVX), and the other underwent 
SHAM surgery. Animals were housed in a temperature-controlled room on a twelve-
hour light and dark cycle, and were provided with ad libitum access to water and 
standard rodent chow (Purina Laboratory Rodent Diet 5001: 23% protein, 4.5% fat, 
6% fiber). After eight weeks we have found that the OVX group manifests significant 
differences in body weight, glucose tolerance, and hepatic TAG composition 
compared to the SHAM group (Jackson, et al., 2011). Thus, tissue was collected eight 
weeks after the OVX or SHAM surgery.  On the day of tissue collection, the mice 
were fasted for 4 hours prior to euthanasia. For one set of mice (n=6/group) the whole 
liver was surgically removed and used to isolate mitochondria as described by Frezza 
et al. (2007).  After isolation, mitochondria were immediately used to assess 
mitochondrial oxygen consumption and H2O2 production. In a second set of 
experiments, livers were surgically removed from another set of SHAM and OVX 
mice (n=8). One half of the liver was snap frozen in liquid nitrogen, and the other half 
was used to isolate mitochondria. The mitochondrial pellet was then isolated and 
stored at  -80°C for subsequent immunoblotting. All aspects of this study were 






Hepatic TAG analysis: Using a small section of liver,  FA’s were measured as 
previously described (Jackson et al., 2011) through a previously described extraction 
procedure (Folch et al., 1957).  
 
Mitochondrial Isolation: Liver tissue was collected and immediately placed in ice-
cold isolation buffer (IBc) containing 10mM Tris-MOPS, 1mM EGTA/Tris, and 
0.2M sucrose (pH 7.4). All procedures were performed in an ice bath to prevent 
mitochondrial degradation. The liver was washed with IBc until the solution was 
clear. Then it was minced with scissors and gently homogenized using a 30ml 
glass/Teflon potter Elvehjem tissue grinder. The homogenate was transferred to a 
conical tube and centrifuged at 600g for 10 minutes at 4°C. The supernatant was 
transferred to a glass centrifuge tube and spun at 7,000g for 10 minutes at 4°C. The 
pellet was re-suspended in 5ml IBc and centrifuged at 7,000g for 10 minutes at 4°C. 
The resulting supernatant was discarded. Then the pellet was loosened with a ice-cold 
glass rod and transferred to a microcentrifuge tube. Any excess buffer solution was 
removed. The protein concentration of the pellet was determined using the Pierce 
BSA protein assay. Only freshly isolated mitochondria were used to measure oxygen 
consumption and H2O2 production, and the remaining mitochondria were stored at -
80°C.  
 
Mitochondrial H2O2 production: Hydrogen peroxide production by isolated 
mitochondria was measured fluorimetically with the oxidation of nonfluorescent 




et al., 2009) using a Synergy H1 plate reader (BioTek). All of these assays were 
measured at 37°C in a black-bottom 96-well plate. Mitochondria (~0.2mg protein) 
was added to respiration buffer (125mM KCl, 2mM K2PO4, 10mM HEPES, 1mM 
MgCl, 0.1mM EGTA, 1%BSA, pH 7.4) with horseradish peroxidase 0.1 U/ml and 
50µM Amplex Red reagent. Mitochondrial H2O2 production was assessed in the 
presence of 500µM glutamate, 25µM malate, 300µM ADP (stage 3 respiration), or in 
the presence of 40µM oligomycin (stage 4 respiration). The content of hydrogen 
peroxide was calculated using a standard H2O2 curve in respiration buffer and 
normalized to the total mitochondrial protein in each well.  Four to five replicates 
were measured from each isolated mitochondrial sample from both groups. 
 
Mitochondrial oxygen consumption: Oxygen consumption was measured  
polarographically using an Oxytherm (Hansatech) as described by Garcia-Cazarin et 
al. (2011). Freshly isolated mitochondria (~150μg) from each group were placed in 
the calibrated electrode chamber containing 500μl of respiration buffer (125mM KCl, 
2mM K2PO4, 10mM HEPES, 1mM MgCl, 0.1mM EGTA, 1%BSA), 0.5mM 
glutamate/0.025mM malate and 300µM ADP (Sigma) as substrates to induce state 3 
or maximal respiration. After 3 minutes, oligomycin (Calbiochem) was added for a 
final concentration of 40µM to induce state 4 (i.e. basal respiration) for 3 minutes. 
This was repeated at least eight times for each sample. To ensure mitochondrial 
integrity, samples were only used when the respiratory control ratio (RCR= state 3 
VO2/ state 4 VO2) fell between 2.49 and 6.0 (Valle et al., 2007).  All mitochondria 





Immunoprecipitation of Acetylated Long Acyl Chain CoA Acetyl Dehydrogenase 
(LCAD): 250µg of protein from the mitochondrial pellet was diluted in a modified 
Mueller buffer (100mM KCl, 50mM HEPES, 5mM MgSO4, 1mM EGTA) and 
incubated in 1:100 dilution of long-chain acyl-CoA dehydrogenase (LCAD) antibody 
rocking overnight in 4°C. High affinity sepharose beads (Sigma) were washed two 
times in 1ml of Mueller buffer and centrifuged at 8,000g for 2 minutes at 4°C. The 
protein-antibody complex was then added to 30µl of washed beads and left rocking 
overnight in 4°C. Beads bound with the antigen-protein complex were then washed 
three times with Mueller buffer and centrifuged at 13,000g for 5 minutes at 4°C, 
followed by the addition of 6.25µl of sample buffer (25mM Tris, 192mM Glycine, 
0.1%SDS). The protein was then loaded in a Mini-PROTEAN®TGX™ Precast Gel 
(BioRad) at 180V for 45 minutes, and transferred onto a PDVF membrane. The blot 
was then incubated in Acetylated-Lysine (1:1000) antibody overnight (diluted in 
5%BSA-TBS-T), and washed with 0.05%TBS-T prior to an hour-long incubation 
with horseradish peroxidase (HRP)-conjugated rabbit secondary antibody (1:1000) in 
a buffer of 3% nonfat dry milk and TBS-T. Membrane was then visualized as 
described below. To assess for LCAD content the blot was stripped by incubating 
membrane in strip buffer at 50°C while rotating at 125RPM for 30 minutes. The blot 
was then probed for LCAD as described below.  
 
Western Blot Analysis of ETC enzymes, protein acetylation, and sirtuin content: 




(ETC) enzymes (MitoSciences) (1:250), acetylated-lysine proteins (1:1000) (Cell 
Signaling), SIRT3 and SIRT1 (1:1000) (Cell Signaling), and LCAD, very long chain 
acyl-Coa dehydrogenase (VLCAD), and medium chain acyl-Coa dehydrogenase 
(MCAD) (1:2500) (kind gift of Dr. Gerald Vockley, University of Pittsburgh). Equal 
amounts of protein (30-35µg) were run in a Mini-PROTEAN®TGX™ Precast Gel 
(BioRad) and transferred onto a PDVF membrane. Blots were blocked for one hour 
using 3% nonfat dry milk dissolved in Tris-buffered saline with 0.05% or 0.01% 
Tween (TBS-T). Following, the membrane was incubated in the appropriate primary 
antibody diluted in TBS-T and 5% BSA overnight in 4°C. The membrane was then 
washed with TBS-T and incubated for one hour with horseradish peroxidase (HRP)-
conjugated secondary antibody (1:1000 for Cell Signaling antibodies and 1:2000 for 
ACAD antibodies) in a buffer of 3% nonfat dry milk and TBS-T. Membranes were 
incubated for one minute in enhanced chemiluminescence reagent (PierceProtein 
Research). Membranes were visualized with a chemiluminescence imager (Syngene, 
Frederick, Md., USA) and quantified with Image J software (National Institutes of 
Health, Bethesda, MD). 
 
Statistical Analysis: To compare means between SHAM and OVX, a one-tailed t-test 
was used for detecting significant differences between groups. Statistical significance 







Anatomical characteristics of SHAM and OVX groups 
The OVX group had 14% higher body weight compared to the SHAM group (Table 
1). In addition, the OVX group exhibited a significant three-fold higher visceral fat 
mass and 121% higher inguinal fat mass compared to the SHAM group.  These 
differences in fat mass were still present even after adjusting to total body weight (p < 
0.01). The liver mass was not different between groups, but it was significantly 
different when adjusted to body weight (P < 0.05). This trend was also seen when 




Hepatic TAG content 
There were no significant differences in hepatic TAG storage between the two groups 
(Fig. 1). However, OVX mice tended to store more hepatic TAG (10.5±1.8 µg/mg) 
than SHAM mice (7.8±1.2µg/mg) (p=0.119).  
Table 1: Anatomical characteristics for SHAM and OVX groups  
 






Body Weight (g) 
22.7±0.5 25.8±0.8*  < 0.01 
Heart  (mg) 134±4 126±4  0.097 
Heart/BW 0.006±0.0001 0.005±8.5E-05* < 0.01 
Visceral Fat  (mg)  260±24 842±69* < 0.01 
VCF/BW 0.011±0.001 0.032±0.003* < 0.01 
Inguinal Fat (mg) 233±14 514±48* < 0.01 
ING/BW 0.010±0.001 0.020±0.001* < 0.01 
Liver (g) 1.08±0.05 1.08±0.08 0.494 
Liver/BW 0.047±0.001 0.042±0.003* <0.05 
    
Values presented as means ± SEM 





Oxygen consumption of hepatic mitochondria 
 The rate of mitochondrial oxygen consumption was measured using glutamate 
and malate as substrates (Fig. 2A).  ADP was added to induce state 3 respiration (i.e. 
maximal respiration), followed by the addition of oligomycin to induce state 4 
respiration (i.e. minimal respiration). No statistical differences were detected in state 
3 or state 4 respiration rates (Fig. 2b), or in the average RCR values (VO2 state 3/ VO2 




























Figure 1: Hepatic TAG content was not 
significantly different between SHAM and 
OVX group (p= 0.119). Bars represent means 

























Figure 2: Example output of hepatic 
mitochondrial oxygen consumption using 
a Hansatech Oxytherm (Fig. 2a). 
Maximal oxygen consumption (State 3) 
was measured when mitochondria were 
provided with 0.5mM  glutamate, 
0.125mM malate, and 300µM ADP. 
Basal oxygen consumption (State 4) was 
induced with 40µM oligomycin. 
Ovariectomy had no effect on hepatic 
mitochondrial O2 consumption during 
state 3 nor state 4 respiration (Fig. 2b). 
Bars represent means ± SEM of 5 







Mitochondrial hydrogen peroxide production 
  
 Hepatic mitochondria from the OVX mice had increased rates of H2O2 
production (Fig.3) in state 3 (p = 0.07) and in state 4 (p < 0.05). 
 
Mitochondrial protein content  
 There were no differences detected between the SHAM and OVX mice 
regarding the protein content of LCAD, MCAD, and VLCAD, which are critical 
enzymes involved in β-oxidation (Fig. 4). There were also no differences in the 
protein content of the five complexes in the ETC (Fig. 5).   
p = 0.07 p < 0.05 
Figure 3: Effect of ovariectomy on 
H2O2 production by hepatic 
mitochondria. Mitochondria were 
incubated with Amplex Red reagent, 
0.5mM glutamate/0.125 malate, 300µM 
ADP (state 3), and 40µM oligomycin 
(state 4) for 30 minutes. Bars represent 
means ± SEM of 5 animals. 
*Represents significance p<0.05. 
 
 
Figure 4: Ovariectomy (closed bars) had no 
effect on the content of MCAD, VLCAD, or 
LCAD proteins in isolated hepatic 
















Acetylation of mitochondrial proteins 
 Acetylation of lysine residues regulates enzymatic activity of numerous 
mitochondrial enzymes. No differences were detected in global acetylation patterns of 
mitochondrial proteins (Fig. 6).  In addition, no significant differences were detected 
in key deacetylase proteins Sirt1 and Sirt3 (Fig. 7) or in the acetylation of LCAD 
(Fig. 8).  
 















Figure 6: Ovariectomy (closed bars) 
had no effect on global acetylation of 
mitochondrial proteins in isolated 
hepatic mitochondria (n=8). Acetylation 
was detected on proteins ~155kDa 
(Peak 1), ~40kDa (Peak 2), and  






Figure 5:  Ovariectomy (closed bars) had no effect on the content of electron transport chain 
(ETC) proteins in isolated hepatic mitochondria (n=8). Bars represent means ± SEM.  
ATPsynthase – 53kD 
Complex III – 47kD 
Complex IV – 39kD 
Complex I – 20kD 






























































Figure 7: Ovariectomy (closed bars) had no effect on SIRT3 content (7a) and SIRT1 content (7b) in 




Figure 8: Ovariectomy (closed bars) had no effect on LCAD acetylation in isolated hepatic 








 Numerous studies including our own have shown that OVX mice develop 
significant alterations in metabolic function in multiple peripheral tissues (Chen et al., 
2009; Mauvais-Jarvis, 2011; Wohlers et al., 2011; Jackson et al., 2011).  Although the 
liver is a key tissue for the regulation of whole-body metabolic function, there are few 
published studies examining the role of ovarian hormone deficiency on hepatic 
metabolic function.  In this study, hepatic mitochondria isolated from OVX mice 
produced higher levels of reactive oxygen species (ROS) during State 4 respiration 
and a trend for increased ROS production in State 3 compared to hepatic 
mitochondria isolated from SHAM mice.   However, there were no differences in any 
other measures of mitochondrial function or in hepatic TAG content despite a two-
fold increase in visceral fat mass in the OVX animals.  These data suggest that 
increased ROS production may contribute to the previously documented onset of 
hepatic steatosis in the OVX animals (Rogers et al., 2009).  The data further indicate 
that metabolic changes in the OVX model occur in a time-dependent manner, and 
thus, in the future more time point based experiments are necessary to completely 
elucidate the mechanisms contributing to the onset of metabolic disease in the OVX 
animals.    
 My data demonstrate for the first time that ROS production is increased in 
mitochondria isolated from hepatic tissue of OVX animals when compared to SHAM 
animals.  Although there was no indication of hepatic steatosis in these animals eight 
weeks following OVX, other groups have reported the development of hepatic 




al. 2009). The tendency for elevated hepatic TAG content in the OVX mouse was 
quantitatively similar to previous findings from my laboratory group (Jackson et al., 
2011).  Thus, it appears that the animals would continue to accumulate hepatic TAG 
if they were allowed to age for a longer period of time following OVX (Rogers et al., 
2009).  The eight-week time point was chosen based on previous data where my 
laboratory group has found significant increases in visceral fat mass in the OVX 
animals (Wohlers et al., 2010) coupled with development of glucose intolerance (data 
not published).  At this time, I am unaware of any other published data demonstrating 
increased mitochondrial ROS production in hepatic tissue from OVX mice. Since the 
increase in ROS production precedes hepatic TAG accumulation in this current study, 
it is possible that ROS production is a critical signal for the development of 
mitochondrial dysfunction that would ultimately contribute to increases in hepatic 
TAG accumulation at later timepoints in the OVX group. 
 Mitochondria utilize an intermembrane hydrogen ion gradient created by the 
movement of reducing equivalents (i.e. NADH and/or FADH) through complex I 
and/or II of the electron-transport chain (ETC) to ultimately drive ATP synthesis in 
the cell.  The movement of the hydrogen ions against the electrochemical gradient is 
possible due to a transfer of electrons across the various complexes of the ETC with 
oxygen (O2) acting as the final electron acceptor. Thus, O2 consumption by the 
mitochondria is necessary for optimal function of the organelle.  In this study, I 
defined mitochondrial dysfunction as reduced respiration rates (as measured by 
mitochondrial O2 consumption) coupled with increased mitochondrial ROS 




mitochondrial dysfunction as evidenced by increased ROS production. Surprisingly, 
my data did not demonstrate any differences in the hepatic mitochondrial O2 
consumption in the OVX group when compared to age-matched SHAM animals. 
However, mitochondrial function encompasses more processes than O2 consumption 
by the electron transport chain (ETC), such as the activity of β-oxidation and the 
Krebs cycle. Other published data have suggested that hepatic mitochondria from 
OVX animals lack the ability to oxidize fatty acids compared to SHAM animals 
(Paquette et al., 2009; Campbell et al., 2003).  These data are somewhat conflicting 
with my own, but are likely due to the different experimental approaches. My 
approach directly addressed function of the ETC, while the other published 
approaches have examined the function of upstream processes of FA oxidation (i.e β-
oxidation and Krebs Cycle function).  Specifically, Paquette et al. (2009) found 
deficiencies in oxidation of radiolabeled palmitate in isolated hepatic mitochondria 
from OVX animals compared to SHAM animals, as determined by reduced release 
rates of radiolabeled CO2. These data suggest that deficiencies in β-oxidation may 
have specifically developed under conditions of reduced ovarian hormone function; 
however, these measures do address ETC function.  On the other hand, my data 
directly addressed hepatic mitochondrial ETC function and suggest that there is no 
deficiency eight weeks following OVX. It is possible that an estrogenic effect acting 
on enzymes specific to β-oxidation is responsible for the discrepant findings, since 
the impact of estrogens on ETC enzymes is unknown (Campbell et al., 2003; Toda et 
al., 2001).  However, I was unable to detect any differences in the protein content of 




of β-oxidation), between the SHAM and OVX animals. However, measuring the total 
protein content does not account for the activation level of these proteins, thus, it is 
possible that their activity is reduced independent of the protein content. 
 Acetylation is a recently described post-translational regulator of 
mitochondrial function (Hirschey et al., 2010). SIRT1 and SIRT3 are the major 
deacetylases that modulate mitochondrial function in response to changes in energetic 
demand (i.e. increases in the NAD+/NADH ratio) by removing acetyl groups bound to 
lysine residues in a given mitochondrial protein sequence (Lombard et al., 2007). 
Growing evidence supports that excessive acetylation decreases the activity of 
proteins involved in lipid oxidation in the mitochondria (Hirschey et al., 2010; Cimen 
et al., 2010; Kendrick et al., 2011).  In addition, Hirschey et al. (2011) found an 
association between increased acetylation of mitochondrial proteins and the 
development of hepatic steatosis and impaired glucose homeostasis. In similar 
fashion to our previously published data in the OVX model, the SIRT3KO model 
develops hepatic steatosis without changes in the function of known lipogenic 
regulators (e.g. SREBP-1c, ACC-1, FAS) (Jackson et al., 2011; Hirschey et al, 2010). 
The SIRT3KO mouse also exhibits impaired palmitate oxidation due to decreased 
activity of LCAD (Hirschey et al., 2010). Thus, based on the number of striking 
similarities between the SIRT3KO mouse and the OVX mouse model, acetylation and 
hepatic SIRT content were measured as a potential mechanism for explaining 
differences in mitochondrial function in the OVX mouse model. However, no 
differences were detected in total acetylation of mitochondrial proteins or in the 




found no differences in total hepatic SIRT1 and SIRT3 content. These observations 
suggest that at eight weeks following OVX there are minimal changes in SIRT 
function and, thus, it appears that changes in deacetylase function do not contribute to 
hepatic TAG accumulation.  
 It has been previously observed that impaired mitochondrial function is often 
associated with hepatic steatosis and insulin resistance.  For example, a decline in 
hepatic mitochondrial function predisposes elderly lean subjects to accumulate 
intrahepatic lipid, contributing to the development of hepatic insulin resistance 
(Petersen et al., 2003; Petersen et al., 2004). This effect corresponds with an increase 
in intrahepatic lipid content, which is associated with a reduction in mitochondrial 
rates of oxidative phosphorylation. However, it is difficult to confirm the order of 
events based on these studies, in that it is hard to determine whether mitochondrial 
dysfunction occured prior to intrahepatic lipid accumulation or vice versa. It is for 
this reason that the implementation of animal studies has allowed researchers to gain 
a better understanding of regulation of hepatic TAG dynamics by the mitochondria. 
A number of animal studies demonstrate that impaired fat oxidation actually 
precedes the development of hepatic steatosis and insulin resistance. Bruce et al. 
(2009) showed that the offspring from mice maintained on a chronic high-fat diet 
exhibit significant declines in mitochondrial function prior to developing hepatic 
steatosis. Similar findings were published by Rector et al. (2010) in the OLETF rat 
model, which develops severe NAFLD due to hyperphagia. This study demonstrated 
that insulin sensitivity was not impaired in OLETF rats until twelve weeks after the 




tissue contributed to the pathology of insulin resistance in this model (Rector et al., 
2010).  Importantly, at only 5 weeks of age (before there are any signs of hepatic lipid 
accumulation) these animals manifest a significantly reduced ability to oxidize lipid 
(Rector et al., 2010). Collectively, these studies indicate that a loss of normal 
mitochondrial function appears to act as a precursor in the development of hepatic 
steatosis and insulin resistance in obesity.  
 Thus, my data suggest that excessive ROS production could potentially be the 
precipitating event that contributes to the development of overt mitochondrial 
dysfunction, ultimately leading to the significant accumulation of lipid in hepatic 
tissue.  Using other experimental models, a few studies have shown that increased 
ROS levels induce mitochondrial dysfunction in hepatocytes due to excessive lipid 
peroxidation. Lipid peroxidation leads to altered permeability of the mitochondrial 
membrane, contributing to the leakage of matrix enzymes and a subsequent alteration 
in the electrochemical gradient that is critical for the synthesis of ATP (Carini et al., 
1992). Increased levels of ROS also play a role in the etiology of alcohol-induced 
fatty liver disease (AFLD). Ethanol induced- mitochondrial ROS production in 
cultured rat hepatocytes led to a 66% increase in lipid peroxidation, which resulted in 
significant mitochondrial dysfunction (Devi et al., 1993). Collectively, these studies 
suggest that ROS-induced mitochondrial dysfunction is an important component of 
the pathology of fatty liver disease, and thus ROS production could be one of the 
initial signals leading to NAFLD in the OVX model.  
 To the best of my knowledge, this is the first study that has shown increased 




have found increased ROS production in in other tissues when estrogen function is 
reduced (Duckles et al., 2010; Strione et al., 2005; Razmara et al., 2008). It is 
suggested that estrogen down regulates ROS production by increasing the expression 
of ROS-scavenging enzymes such as catalase (Toda et al., 2001) and glutathione 
(Valle et al., 2007). Further, estrogen treatment increased levels of ROS-scavenging 
enzymes in brain endothelial cells from OVX mice (Razmara et al., 2008) so it is 
possible that OVX results in excess ROS production by hepatic mitochondria due to a 
loss in the activity of ROS-scavenging enzymes.  
 Ovarian dysfunction or inhibition of estrogen function in women increases the 
risk for NAFLD, insulin resistance, and ultimately the MetS.  An estimated 20-30% 
of middle-aged women have MetS, but the prevalence escalates significantly after the 
onset of menopause, resulting in increased mortality risk in this population (Janssen 
et al., 2008; Ervin, 2009). The data presented here show that ovarian dysfunction is 
associated with an increase in ROS production by hepatic mitochondria, which I have 
hypothesized to be a potential signal for the development of hepatic metabolic 
dysfunction under conditions of reduced ovarian function.  Due to the importance of 
the liver in the regulation of metabolic function, increased ROS production may be a 
significant contributor to the development of overt metabolic disease in post-
menopausal women. Therefore, if we can target the single initial metabolic change 
that is induced by ovarian dysfunction, such as a rise in hepatic mitochondrial ROS 
production, we may drastically improve and even prevent the consequential metabolic 






Limitations and Delimitations 
  This study used eight-week old C57Bl/6 mice to study the effects of a 
reduction in female sex hormones on metabolic function.  This design does not 
consider the effect of aging, which is yet another factor affecting the rate of hepatic 
lipid accumulation. For this reason, my research approach is appropriate to study how 
reduced ovarian function affects hepatic metabolism without aging as a confounding 
variable; however, I also cannot account for the effect of age on hepatic lipid 
accumulation using this model.   
 Moreover, studies suggest that a reduction in female sex steroid hormones 
increases appetite in some animals, like the OVX rat, which may affect hepatic 
metabolism differently. Based on unpublished data from my lab group and previous 
publications (Rogers et al., 2009), the OVX mouse model does not show signs of 
hyperphagia, but does show significant loss of spontaneous physical activity levels 
that could influence my results, independent of the ovarian hormone status.  Physical 
activity is also a critical regulator of hepatic mitochondrial function in the liver, thus 
this is a likely key factor that needs to be considered (Rector & Thyfault, 2011). 
Furthermore, estrogen can affect numerous different tissues, such as skeletal muscle 
and adipose tissue, both of which may influence whole body metabolism as well as 
hepatic metabolism. Therefore, by using this model I could not account for the effects 
of estrogen in tissues other than the liver. 
 Finally, evidence suggests that this OVX model reproduces a number of 




However, it is not clear if the mechanisms affected would be the same in mice and 
humans, especially when there are inconsistencies in the effects of ovariectomy 
between different types of rodents.  Nevertheless, this is a starting point for defining 




 In this study I provided evidence for hepatic mitochondrial ROS production to 
be the initiating factor for further mitochondrial dysfunction that predisposes the liver 
to fat accumulation and insulin resistance in the OVX model. However, the OVX 
model exhibits other confounding variables such as increased visceral fat mass and 
decreased physical activity that could also affect hepatic mitochondrial function. In 
order to isolate the effects of estrogen function to the liver alone, it would be an 
appropriate next step to genetically knock out the estrogen receptor in hepatic tissue 
(LERKO). I would hypothesize that LERKO animals would have normal body 
weight, visceral fat mass, and physical activity levels at an early stage when hepatic 
metabolism is not fully impaired. This approach would allow me to examine 
mitochondrial function and hepatic TAG content at different time points in LERKO 
mice independent of secondary changes seen in the OVX model that could influence 
hepatic tissue function. This study would then provide insight as to the effects of 
estrogen on hepatic mitochondrial function and to determine whether ROS production 





Review of Literature 
 
The metabolic syndrome increases the rate of mortality  
 The rate of mortality is increasing in the United States partially due to the high 
incidence rates of cardiovascular disease, cancer, and type 2 diabetes (Centers for 
Disease Control and Prevention [CDC], 2010; Lakka et al., 2002). These conditions 
are linked to the Metabolic Syndrome (MetS). Currently, it is estimated that over a 
third of the population over the age of 20 has the MetS (Nedungadi & Clegg, 2009), 
making it a critical risk factor for mortality in the American population. 
 
 
Insulin resistance is a main characteristic of the metabolic syndrome 
 A cluster of metabolic abnormalities gives rise to the MetS, including visceral 
adiposity, insulin resistance, dyslipidemia, and hypertension (NCEP, 2001). However, 
the most accepted and unifying hypothesis to describe the pathophysiology of the 
MetS is the development of insulin resistance (IR) (Eckel et al., 2005; Grundy et al., 
1999), which is characterized by defective insulin action resulting in a dysregulation 
in blood glucose levels.  Insulin resistance predisposes multiple organs to 
metabolic abnormalities, such as increased glucose and lipoprotein secretion by the 
liver (Austin et al., 1996; Haffner et al., 1995), increased secretion of fatty acid (FA) 
by adipose tissue (Mostazza et al., 1998), and impaired vasodialation of endothelial 
cells (Steinberg et al., 1996). Therefore, the metabolic abnormalities that give rise to 




Insulin resistance is associated with visceral adiposity  
 The risk of becoming insulin resistant is strongly associated with the 
development of visceral adiposity. It was reported that the strongest predictor for 
common manifestations of insulin resistance (i.e. increased circulating glucose, 
insulin, and triglycerides) was the waist-to-hip ratio (Evans et al., 1984). Which 
suggests that the distribution of fat in the abdominal area versus gluteal region 
increases the risk for insulin resistance (Evans et al., 1984). In addition, abdominal 
adiposity is associated with developing impaired fasting glucose over a 5-year period 
(Guthrie et al., 2001). Moreover, it was suggested that in order for visceral fat to 
promote insulin resistance in women, visceral fat mass had to reach a certain 
threshold that was comparable to the levels found in men (De Nino et al., 2001). 
Therefore, the volume of fat in the visceral region is highly associated with the 
development of insulin resistance.  
  
 
Visceral adiposity is associated with increased hepatic lipid storage 
 Obesity is often associated with the development of non-alcoholic fatty liver 
disease (NAFLD), which is characterized by increased hepatic triacylglycerol (TAG) 
accumulation (>5% of total liver mass) in the absence of excess alcohol consumption 
(Rector & Thyfault, 2011). NAFLD is the most common chronic liver disease 
worldwide, affecting more than 75% of all obese individuals (Thorne et al., 2010). 
Because of the high prevalence of NAFLD in obesity, it is suggested that visceral 




most of hepatic TAG (~60%) in NAFLD patients comes from circulating FFA 
derived from visceral adipose tissue (Donnelly et al., 2005).  This association was 
evident when comparing adipose tissue distribution through CT scans and hepatic 
lipid storage using liver biopsies from healthy human subjects (Parks et al., 2007). 
This study found that some of the predictors for hepatic steatosis were BMI, increased 
alanine aminostrasferase (ALT), low levels of high-density lipoprotein (HDL), and 
the ratio between visceral to subcutaneous fat. However, the strongest predictor for 
risk and degree of hepatic steatosis in both men and women was the mass of visceral 
fat, which led to the conclusion that visceral fat is an independent risk factor for 
hepatic steatosis in both men and women.  
 
 
Hepatic lipid storage is a strong predictor for insulin resistance 
 Current studies using non-invasive imaging techniques support the idea that 
intrahepatic fat (IHF) is a stronger predictor of insulin resistance than visceral fat 
(Hwang et al., 2007; Gentile et al., 1993; Kotronen et al.,2008). This concept is 
further supported in patients with type 2 diabetes, as the content of intrahepatic fat 
(IHF) was closely correlated with the sensitivity to endogenous insulin, insulin dose, 
and it often explained the variation in insulin requirements between subjects (Gentile 
et al., 1993). Also, IHF was the only independent predictor of insulin mediated 
glucose disposal when compared to visceral adipose tissue and intramyocellular lipid 








Loss of ovarian function increases the risk for the metabolic syndrome 
 Women over the age of 40 who have the MetS are at a much higher risk for 
not only cardiovascular-mortality, but all-cause mortality as well (Lin et al., 2010). 
More women are affected by MetS than men once they reach the age of 60 (Ervin, 
2009), an age in which women are menopausal (Reyes, 1977). In a longitudinal study, 
it was estimated that 20%-30% of middle aged women have the MetS, but it was 
observed that the incidence rate of the MetS increased steadily after the onset of 
menopause (Janssen et al., 2008). This is evidenced by the higher fasting insulin and 
glucose levels reported in post-menopausal women when compared to premenopausal 
women (Poehlman et al., 1997; Razay et al., 1992; Lynch et al., 2002). Lindheim et 
al. (1994) also found that postmenopausal women had decreased insulin sensitivity 
compared to age-matched premenopausal women, which suggest that the onset of 
metabolic defects are a direct result of menopause instead of age alone. The metabolic 
syndrome was also highly prevalent in women with bilateral oophorectomy (Dorum 
et al., 2007), and recent data also show that oophorectomy before the age of 40 in 
overweight women were more than twice as likely to die from CVD than same-age 
non-obese women with intact ovaries (McCarthy et al., 2012). Collectively, the data 





Loss of ovarian function increases visceral adiposity  
 Obesity is more prevalent among middle-age women than in men, with 
approximately two thirds of women between 40 to 60 years of age being overweight 
or obese (Ogden, 2006). One of the major contributing factors to the development of 
adiposity during a woman’s life is the onset of menopause (Polotsky, 2010), which is 
a period when ovarian hormone production is substantially reduced (Reyes, 1977). 
Pre-menopausal women tend to store more subcutaneous fat, but women exhibit 
significant increases in visceral fat mass with the onset of menopause (Janssen et al., 
2008); however, these data are based from cross-sectional studies, and their findings 
are not fully consistent with those reported by Lovejoy et al. (2008). In a longitudinal 
study of over a hundred women, it was reported that visceral fat increased throughout 
the four years prior to the onset of menopause, and it also remained relatively stable 
after the first two years of menopause (Lovejoy et al., 2008). However, the increase in 
adiposity was associated with decreased levels of circulating estradiol before 
menopause, which is consistent with the hypothesis that a decrease in estrogen 
influences the gain in visceral adiposity (Lovejoy et al., 2008; Sowers et al., 2005).  
 Due to the multifactorial nature of the onset of obesity in women, various 
animal models have been employed to study the effects of female sex steroids on 
metabolism.  These animal models allow for better control over other factors 
including, genetics, food intake and age that may contribute to the development of the 
MetS.  A number of animal models have been employed including: ovariectomized 
female mice (OVX), estrogen receptor knockouts (ERKO), and aromatase knockouts 




has a 70-90% reduction in circulating estrogens (Gorzek et al., 2007; Sitnick et al., 
2006) which is associated with a significant increase in body weight (~25%) and 
visceral adiposity (over 100%) independent of changes in food intake (Wohlers et al., 
2011; Rogers et al., 2009). Similar increases in adiposity are evident in mice lacking 
the aromatase enzyme (ARKO), which is responsible for endogenous estrogen 
production (Hewitt et al., 2004), and the ERαKO mice (Bryzgalova et al., 2005). In 
fact, visceral adiposity is one of the most striking and apparent metabolic changes 
induced with reduced function of ovarian hormones. Moreover, various studies have 
supporting evidence that the metabolic changes occur as a result of decreased 
estrogen function, as treatment with estradiol or estrogen receptor agonists often 
prevent or even reverse excess visceral adiposity (Brygazlova et al., 2005; Hewitt et 
al., 2004; D’Eon et al., 2005; Turgeon et al., 2006).  
 
Visceral fat deposits fatty acids into the liver  
 Most of stored hepatic lipid appears in the form of triacylglycerol (TAG), of 
which the majority is derived from portal circulation (Donnelly et al., 2005). 
Increases in circulating FFA are often the result of the hydrolysis of TAG (i.e. 
lipolysis) in different tissue depots. It is well established that visceral adipose tissue 
has increased lipolytic activity compared to subcutaneous adipose tissue (Arner, 
1995). Thus, the lipolytic activity of visceral fat is related to hepatic fat accumulation, 
as FFAs released from this tissue have direct access to the liver through the portal 




acid transport protein-2 and 5 (FATP2, FATP5) or fatty acid translocase (FAT/CD36) 
then facilitate FFA entry into the liver from the portal circulation.  
  There is also evidence that the release of FFA by adipose tissue is more 
strongly associated with adipocyte cell size rather than fat mass (Laurencikiene et al., 
2011; Koska et al., 2008). Larger adipocytes have an enhanced lipolytic rate 
compared to small adipocytes in basal (un-stimulated) conditions (Laurencikiene et 
al., 2011). Thus, adipocyte size is strongly linked to the risk for type 2 diabetes and 
CVD (Koska et al., 2008). Evidence from my lab group has found that the increase in 
visceral fat mass in the OVX animal model is due to increased adipocyte size and not 
due to increased adipocyte number (Wohlers & Spangenburg, unpublished). In 
addition, isolated adipocytes and adipose tissue explants from OVX animals exhibit 
increased circulating FFA and glycerol under basal conditions and impaired lipolysis 
when stimulated with catecholamines (D’Eon et al., 2005, Wohlers & Spangenburg, 
unpublished). Conceptually, these data suggest that under conditions of chronic 
ovarian dysfunction an increase in visceral fat mass leads to unregulated release of 
FFA into the portal circulation, which may contribute to increased hepatic lipid 
deposition.  
 
Loss of ovarian function in women increases their risk for NAFLD 
 With the onset of menopause the prevalence of NAFLD is higher in women 
than men (Nomura et al., 1988; Kojima et al., 2006; Park et al., 2006). If untreated, 
the progression of NAFLD leads to non-alcoholic steaohepatitis (NASH), chronic 




women when looking across the entire population (Massard et al., 2006; Poynard et 
al., 2001). A population-based study in Japan gave evidence that at the age of 60 
women were more likely to have NAFLD than men of the same age (Nomura et al., 
1988; Kojima et al., 2006). Similar reports were made in the American population by 
the NHANES study (Clark et al., 2007). The NHANES study also indicated that the 
prevalence of NAFLD is greater in postmenopausal women compared to both 
premenopausal women and postmenopausal women under hormone replacement 
therapy (HRT). Thus epidemiological data suggest that the menopausal status in 
women is associated with the risk for developing NAFLD, and that normal ovarian 
function may protect the liver from excess lipid accumulation that may lead to 
NAFLD.  
 
Excessive hepatic fat accumulation causes hepatic insulin resistance and 
impaired glucose homeostasis 
 NAFLD is commonly referred to as the hepatic manifestation of the MetS 
(Bruce et al., 2009; Brunt 2004). This concept is supported by evidence showing that 
obese women with the high amounts of hepatic lipid content also had elevated plasma 
glucose levels and HOMA index (Thorne et al., 2010). Severe insulin resistance can 
also be found in lean, young and older subjects, which is associated excess lipid 
accumulation in the liver (Petersen et al., 2003; Petersen et al, 2004). However, 
because of the nature of these cross-sectional studies, it is impossible to determine 
whether hepatic steatosis causes insulin resistance, or whether insulin resistance 




accumulation and glucose homeostasis at different ages and time points have allowed 
us to gain a better understanding on the series of events causing the relationship 
between hepatic steatosis and insulin resistance.  
 Evidence from animal studies suggests that hepatic lipid accumulation 
precedes insulin resistance (Rector et al. 2010; Bruce et al., 2009). This was evident 
in rodents with diet-induced obesity that developed insulin resistance 12 weeks after 
evidence of hepatic steatosis (Rector et al., 2010). In addition, rodents did not exhibit 
abnormal glucose and insulin homeostasis until 15 weeks after manifesting signs of 
NASH (Bruce et al., 2009). However, Ibdah et al. (2005) had different findings as 
insulin resistance overlapped with the development of hepatic steatosis in rodents 
with impaired hepatic mitochondrial function (Ibdah et al., 2005). However, the 
reduction of hepatic TAG content in rodents by inducing hepatic fat oxidation, was 
able to improve both insulin sensitivity in peripheral tissues and whole body glucose 
homeostasis (Jie et el., 2004). Collectively, these studies suggest that hepatic steatosis 
is highly associated with insulin resistance and often precedes its manifestation.  
 
Impaired hepatic mitochondrial function precedes TAG accumulation the liver 
 Most of the FA delivered to the liver are oxidized by the mitochondria, thus a 
reduced mitochondrial capacity is associated with increased lipid storage in the 
muscle and liver. Mitochondria regulate FA oxidation through a number of dynamic 
regulatory pathways. The FA enters the mitochondria through carnitine-palmitoyl 
transferase 1 (CPT-1), which catalyzes the conversion of FA-CoA into FA-carnitine 




by β-oxidation to be used as a substrate for the Kreb’s Cycle. The electron-transport 
chain (ETC) then utilizes a proton gradient driven by the flow of electrons from 
reducing equivalents produced by the Krebs cycle (i.e. NADH and FADH2), in order 
to drive the synthesis of ATP.    
 The loss of mitochondrial function can occur for a variety of reasons. For 
example, a build-up of acetyl-CoA can occur if the flux from β-oxidation exceeds the 
activation of the ETC, which results in the inhibition of CPT-1 (through allosteric 
inhibition by malonyl-Coa) and halting further fat oxidation. This excess flux can also 
lead to increased ROS production by the ETC (Fischer-Wellman & Neufer, 2012). 
Therefore, when the flux of lipid exceeds the capacity for hepatic mitochondria to 
oxidize it, fatty oxidation is inhibited which ultimately contributes to enhanced 
hepatic lipid storage.   
 A reduced enzymatic capacity of mitochondria to oxidize fat has also been 
associated with increased lipid storage in the muscle and liver. For instance, it was 
reported that obese individuals had a 3 to 4-fold reduction in ETC activity in skeletal 
muscle mitochondria compared to age-matched lean subjects. Moreover, in obese 
subjects with type 2 diabetes, ETC activity was decreased by 7-fold compared to lean 
subjects (Ritkov et al., 2005). Furthermore, lean individuals with reduced oxidative 
capacity in mitochondria from skeletal muscle (Petersen et al., 2003) and liver, 
(Petersen et al., 2004) exhibited TAG accumulation in each respective tissue, as well 
as severe insulin resistance despite their lean phenotype.  
 The link between mitochondrial function, tissue lipid accumulation, and 




2009; Ibdah et al, 2005). Impaired mitochondrial function was the primary event 
mediating fat deposition in the liver in rats selectively bred with low aerobic capacity 
(Thyfault et al., 2009). These rats manifested hepatic steatosis as well as impaired 
palmitate oxidation, reduced β-HAD activity, and reduced mitochondrial content. A 
similar loss in mitochondrial capacity was evident with diet induced-obesity, which 
triggered the development of hepatic steatosis three weeks after measurable 
impairments in mitochondrial function (Rector et al., 2009).  Moreover, hepatic 
steatosis was evident in even in the absence of excess abdominal fat, suggesting that 
lipid accumulation was not due to increased flux from visceral adipose tissue, and 
rather due to impaired fat oxidation in the liver (Bruce et al., 2009). More strikingly, 
when these mice were challenged with a chronic high-fat diet, they developed 
extensive hepatic fat accumulation, impaired glucose homeostasis, and inflammation 
resulting in a diagnosis of NASH. Moreover, it has been shown that obese rats with 
hepatic steatosis do not show signs of insulin resistance until 12 weeks after the onset 
of hepatic TAG accumulation (Rector et al., 2009). These studies provide insight 
towards the importance of the capacity of mitochondria to oxidize fat as in preventing 
the development of hepatic steatosis and insulin resistance. Therefore, fat oxidation 
may be a critical target in the prevention of metabolic disease.  
 
Lipid promotes insulin resistance by promoting the phosphorylation of serine 
residues of IRS 
 Excess lipid accumulation promotes insulin resistance via activation of known 




receptor substrate-1 (IRS-1). For example, lipid metabolites can activate protein 
kinase C (PKCθ) in skeletal muscle (Kim et al., 2004) and PKC-ε in hepatic tissue 
(Samuel et al., 2004) resulting in loss of insulin-induced glucose regulation in both 
tissues. Lipid intermediates such as DAG and fatty-acyl CoA can act as ligands for 
the induction of PKC in hepatocytes (Neschen et al., 2005). Furthermore, by reducing 
the DAG content in hepatic tissue it is possible to protect mice from developing 
NAFLD (Engeli, 2008). Finally, the critical role of PKC was elucidated using mice 
lacking the PKC gene, which was used to demonstrate that the lack of PKC protected 
mice from developing fat-induced insulin resistance (Kim et al., 2004). These data 
suggest that by encouraging complete oxidation of hepatic FA it would be possible to 
reduce the activation of PKC by any fat metabolites, and maintain insulin sensitivity 
in the liver.  
 
Hepatic TAG accumulation and insulin resistance occur in states of reduced 
ovarian function 
 Evidence suggests that estrogens play a protective role in the liver by 
attenuating the development of hepatic steatosis (Cole et al., 2010; Maffei et al., 
2004; Anezaki et al., 2009). For instance, over 50% of women with normal liver 
function who were undergoing cancer treatment with tamoxifen, an estrogen 
antagonist, developed hepatic steatosis, elevated blood triglycerides, and fasting 
blood glucose (Akhondi-Meybodi et al., 2011). Aromatase deficient male patients, 
who lack the ability to make endogenous estrogen, exhibit insulin and glucose 




induced a significant reduction in hepatic lipid storage and improved insulin 
sensitivity in these same men (Maffei et al., 2004). Estrogen therapy was also 
effective in decreasing the incidence of type 2 diabetes even after adjusting for BMI 
or waist circumference in postmenopausal women participating in the Women’s 
Health Initiative (2002), which Suzuki et al. (2009) suggested was the result of 
estrogen preventing the development of NAFLD. 
 This is similar to findings in animal models that accumulate hepatic fat under 
conditions of reduced estrogen function. For instance, mice treated with tamoxifen 
develop hepatic steatosis and insulin resistance without changes in food intake or 
body weight (Cole et al., 2010). Also, both ERKO and ARKO mice developed 
hepatic steatosis (Bryzgalova et al., 2008; Hewitt et al., 2004), which was prevented 
by estrogen administration in ArKO mice (Hewitt et al., 2004). A sex dimorphism in 
hepatic metabolism was also evident in a clinical model of non-alcoholic 
steaohepatitis (NASH) as female mice had reduced levels hepatic fat accumulation 
when compared to male mice (Anezaki et al., 2009). This suggests that ovarian 
function is protective against hepatic lipid accumulation. Furthermore, ovariectomy 
also results in hepatic steatosis and insulin resistance in rodents. Lavoie et al, (2007) 
has shown that ovariectomy induces the accumulation of TAG in the hepatic tissue of 
rats. This occurs independent of the previously reported hyperphagic effect of 
estrogen in this model (Paquette et al., 2007). After 12 weeks of ovariectomy mice 
also exhibit evidence the development of hepatic steatosis (Rogers et al., 2009, 
Jackson et al., 2012).  Overall, in both humans and animals the loss of estrogen 




development of insulin resistance, which would be expected to contribute to the 
development of NAFLD and ultimately the MetS. 
 
Mitochondrial function and fat oxidation is impaired in hepatic tissue under 
conditions of reduced female sex steroid function  
 Evidence suggests that ovarian hormones enhance the capacity for 
mitochondria to oxidize fat (Campbell et al., 2005; Valle et al., 2007; Bryzgalova et 
al., 2005). For instance, Valle et al. (2007) showed that hepatic mitochondria from 
female mice exhibited increased activity of Complex I and III of the ETC resulting in 
increased rates oxygen consumption by the mitochondria when compared to male 
mice. Conversely, ovarian dysfunction also leads to reductions in fat oxidation.  For 
example, OVX rats had a 34% decrease in hepatic palmitate oxidation compared to 
controls and a 114% increase in liver TAG storage (Paquette et al., 2009). 
Ovariectomy also induced hepatic steatosis in mice that was associated with 
decreased oxygen consumption through indirect calorimentry without differences in 
energy intake compared to SHAM mice (Rogers et al, 2009). Furthermore, ArKO 
exhibited reductions in MCAD expression, a key enzyme in β-oxidation, which 
appears to contribute to the development of hepatic steatosis (Toda et al., 2001).  
 In non-hepatic tissue, evidence also suggests that ovarian function promotes 
the expression and activity of mitochondrial oxidative enzymes. Estrogen treatment 
induced a 7-fold increase in CPT-1 transcription in skeletal muscle, increased CPT-1 
activity, and restored β-HAD activity (Campbell et al, 2003). As expected, in 




(Campbell et al., 2001).   Thus, the data suggest that estrogens have a powerful effect 
on mitochondria, and ovarian function appears to be critical to the maintenance of 
optimal mitochondrial function.  
 
CONCLUSION: Collectively, the evidence suggests that impaired hepatic 
mitochondrial function in states of reduced ovarian function promotes TAG 
accumulation in the liver, resulting in insulin resistance. Currently 20%-30% of 
middle-aged women have the MetS, and its prevalence escalates with the reduction in 
ovarian function caused by menopause.  This is a critical matter to resolve as MetS 
increases the risk for CVD, which is the leading cause of death in women. Insulin 
resistance is one of the main characteristics of the MetS, and evidence suggests that 
mitochondrial dysfunction may be a pathological cause of insulin resistance by 
promoting hepatic lipid accumulation.  Therefore, the mechanisms involved in 
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